gw-799388 and Cachexia

gw-799388 has been researched along with Cachexia* in 1 studies

Other Studies

1 other study(ies) available for gw-799388 and Cachexia

ArticleYear
Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting.
    Scientific reports, 2019, 07-08, Volume: 9, Issue:1

    Cancer mediated activation of the ActRIIB-ALK4/5 heterodimer by myostatin is strongly associated with muscle wasting. We investigated in vitro and in vivo the efficacy of ALK4/5 receptor blockers SB431542 and GW788388 in preventing muscle wasting, and explored synergy with IGF-I analogue LONG R3 (LR3) IGF-I. In vitro, C2C12 skeletal muscle cells were treated with vehicle, SB431542, GW788388 and LR3 IGF-I. A C26-CD2F1 cachexia model was used to induce cachexia in vivo. Mice were allocated as non-tumour bearing (NTB) or C26 tumour-bearing (C26 TB) vehicle control, treated with SB431542, LR3 IGF-I, SB431542 and LR3 IGF-I, or GW788388 (intraperitoneally or orally). In vitro, differentiation index and mean nuclei count increased using SB431542, GW788388, LR3 IGF-I. In vivo, GW788388 was superior to SB431542 in limiting loss of bodyweight, grip-strength and gastrocnemius weight. and downregulated Atrogin-1 expression comparable to NTB mice. LR3 IGF-I treatment limited loss of muscle mass, but at the expense of accelerated tumour growth. In conclusion, treatment with GW788388 prevented cancer cachexia, and downregulated associated ubiquitin ligase Atrogin-1.

    Topics: Activin Receptors, Type I; Administration, Oral; Animals; Benzamides; Body Weight; Cachexia; Cell Differentiation; Cell Line; Colonic Neoplasms; Dioxoles; Gene Expression Regulation; Injections, Intraperitoneal; Insulin-Like Growth Factor I; Male; Mice; Neoplasm Transplantation; Pyrazoles; Receptor, Transforming Growth Factor-beta Type I

2019